


# Syndication Dynamics and Cap Table Dilution Risk in Healthcare Startups

OCT 21, 2025



Share

*Disclaimer: The views and opinions expressed in this essay are solely my own and do not reflect the views, positions, or policies of my employer or any affiliated organizations.*

## ABSTRACT

This essay examines the intricate dynamics of syndication in healthcare startup financing and the often-underestimated risks of cap table dilution. While syndication offers clear benefits including risk distribution, enhanced due diligence, and expanded networks, healthcare entrepreneurs face unique challenges in managing multiple investors with diverging priorities around regulatory compliance, clinical validation timelines, and reimbursement strategies. The essay explores how healthcare startups experience dilution patterns that differ significantly from pure software plays, analyzes the compounding effects of multiple financing rounds required to navigate FDA clearance and payer adoption, and provides frameworks for entrepreneurs to model dilution scenarios while maintaining strategic control. Key findings suggest that healthcare founders who reach Series B retain approximately 25 percent equity compared to 25-35 percent for traditional SaaS founders, driven by longer development cycles and capital intensity. The essay concludes with practical strategies for optimizing syndicate composition and preserving founder ownership through alternative financing structures.

## TABLE OF CONTENTS

Introduction: The Double-Edged Sword of Syndicated Capital

Why Healthcare Startups Syndicate Differently

The Mathematics of Progressive Dilution

Regulatory Complexity and Its Syndication Implications

Strategic Misalignment Among Healthcare Syndicates

The Reimbursement Timeline Problem

Defensive Strategies for Cap Table Management

Alternative Financing Structures in Healthcare

When Dilution Becomes Existential

Conclusion: Rethinking Capital Efficiency

## **Introduction: The Double-Edged Sword Syndicated Capital**

There exists a peculiar tension in healthcare venture capital that few entrepreneurs fully appreciate until they are several rounds deep into their financing journey. On one side sits the conventional wisdom that syndication is universally beneficial, bringing diverse expertise, expanded networks, and validation through the collective judgment of sophisticated investors. On the other side lurks a mathematical reality that becomes increasingly uncomfortable as each new investor joins the cap table: dilution is not just inevitable but potentially catastrophic to founder ownership control. This tension is amplified exponentially in healthcare startups, where the combination of extended development timelines, regulatory uncertainty, and capital-intensive scaling creates a perfect storm for ownership erosion that can leave founders with single-digit equity stakes before their company reaches meaningful commercial traction.

The healthcare entrepreneur embarking on their first institutional fundraising typically approaches syndication with an optimistic framework borrowed from the broader

startup ecosystem. They understand intellectually that giving up twenty percent their company in a Series A is standard, and they may even feel fortunate to have multiple term sheets offering the opportunity to select investors who bring complementary value beyond capital. What often escapes notice during these early celebrations is that healthcare companies rarely follow the neat three-round funding trajectory that software companies might navigate between inception and exit. Instead, they frequently require five, six, or even seven rounds of institutional capital to traverse the regulatory gauntlet, build clinical evidence, establish reimbursement pathways, and scale commercial operations. Each of these rounds introduces new investors, new preferences, and new dilution that compounds in ways that can surprise even financially sophisticated founders.

The mathematics of dilution are deceptively simple on their surface but become Byzantine in practice as option pools refresh, down rounds introduce punitive terms, and bridge financings fill gaps between major rounds. A founder who begins with eighty percent ownership after friends and family funding might find themselves with sixty percent post-seed, forty-five percent post-Series A, thirty percent post-Series B, and twenty percent post-Series C. By Series D, which many healthcare companies require simply to fund the expensive commercial scaling phase after regulatory clearance, that same founder may be staring at twelve to fifteen percent ownership. These are not hypothetical scenarios but empirically observed patterns among dozens of health and medical device companies that have successfully navigated to growth financing.

The syndication dynamics that drive this dilution pattern in healthcare differ fundamentally from those in traditional software ventures. While a consumer internet company might syndicate a Series A to combine a growth-stage investor's scaling expertise with a specialized firm's product development support, healthcare companies syndicate rounds to assemble the Byzantine combination of regulatory strategy, clinical validation expertise, health system relationships, payer negotiation experience, and traditional venture scaling knowledge required to succeed. This necessity for specialized, often non-overlapping domains of expertise creates large

syndicates with more diverse agendas, which in turn creates governance complexities that can paralyze decision-making at critical junctures.

## Why Healthcare Startups Syndicate Differently

Healthcare syndication patterns reveal themselves as distinctly different from pure technology plays when examined through the lens of investor specialization and tolerance. A typical enterprise SaaS company raising a Series A might bring in two investors: a lead who provides the majority of capital and strategic guidance, and a meaningful participant who adds specific go-to-market expertise or customer relationships. The round closes quickly, the cap table remains manageable, and the company proceeds to execute against relatively predictable SaaS metrics around customer acquisition cost, lifetime value, and net revenue retention.

Healthcare startups face a radically different landscape. Consider a digital therapeutics company developing a prescription software application for chronic disease management. This company requires investors who understand FDA regulatory pathways for software as a medical device, clinical trial design and execution, real-world evidence generation, health economic outcomes research, reimbursement strategy, pharmaceutical partnerships for potential distribution, electronic health record integration challenges, and traditional SaaS metrics. Finding all of this expertise within a single firm is virtually impossible, which necessitates syndication across multiple specialized investors.

The result is that healthcare Series A rounds frequently involve three to five institutional investors rather than two. This expanded syndicate structure introduces immediate dilution pressure because each investor requires a minimum ownership percentage to justify their investment and board participation. Where a software company might raise ten million dollars from two investors each taking twelve percent of the company, a healthcare company raising the same amount might not allocate eight percent to a specialized healthcare lead, six percent to a corporate venture arm with distribution relationships, five percent to a clinical-focused in

and four percent to a generalist growth firm, resulting in twenty-three percent dilution versus twenty-four percent in the software example. The difference appears marginal at this stage but becomes compounding as subsequent rounds follow similar patterns.

Beyond the expertise requirements, healthcare syndication is driven by risk diversification around regulatory binary events. FDA clearance or approval processes introduce pass-fail moments that can render a company worthless overnight. No single investor wants concentrated exposure to this regulatory risk, which drives syndication across a larger number of participants who each take smaller positions. This risk diversification is rational from the investor perspective but creates capital bloat that limits the ability to maintain pro-rata ownership in subsequent rounds, forcing additional dilution as new investors demand meaningful stakes.

The timeline implications of healthcare development further exacerbate syndication complexity. While software companies might achieve product-market fit and meaningful revenue within eighteen to twenty-four months of institutional funding, healthcare companies frequently spend three to five years in development and validation before generating substantial revenue. This extended timeline means early investors need to reserve capital for multiple follow-on rounds, and companies need to continually add new investors who are not already over-allocated to the cap table. The revolving door of new syndicate members, each requiring education on the company's technology, regulatory strategy, and market dynamics, creates organizational drag that compounds with each financing round.

## **The Mathematics of Progressive Dilution**

Understanding dilution requires moving beyond simple percentage calculations to examine the compounding effects of multiple financing rounds, option pool refreshments, and the impact of liquidation preferences on effective ownership. The standard venture capital financing structure involves selling preferred stock with a liquidation preference, typically one-times the investment amount, which means preferred shareholders receive their investment back before common shareholders see any

proceeds. In single-exit scenarios this structure is relatively benign, but in the case of multiple rounds at increasing valuations with stacking preferences, the mathematics become increasingly founder-unfriendly.

Consider a healthcare startup that raises a two-million-dollar seed round at an eight-million-dollar post-money valuation, resulting in twenty-five percent dilution. The company then raises an eight-million-dollar Series A at a thirty-two-million-dollar post-money valuation, resulting in twenty-five percent dilution of the post-seed base. At this point, the founder who started with eighty percent ownership now owns approximately forty-five percent on a fully diluted basis. This seems manageable and aligns with typical software company dilution patterns.

The divergence emerges in subsequent rounds. The company requires eighteen months to complete a pivotal clinical study before raising Series B, during which it burns through most of its Series A capital. Market conditions have shifted, and while the clinical data is positive, it is not definitively compelling for payers. The Series B is raised at a sixty-four-million-dollar post-money valuation, a modest 1.56-times step-up that reflects investor caution around reimbursement uncertainty. The company raises sixteen million dollars, resulting in twenty-five percent dilution. The founder now holds approximately thirty-four percent.

Two years later, the company has achieved FDA clearance but is struggling to secure payer contracts at anticipated pricing levels. A Series C is necessary to fund the commercial team build-out and sustained payer negotiations. The round is raised at a one-hundred-million-dollar post-money valuation, a more modest 1.56-times step-up reflecting continued execution risk. Twenty-five million dollars is raised, again at approximately twenty-five percent dilution. The founder now holds approximately twenty-five percent.

The company finally begins generating meaningful revenue but needs to fund the transition from early adopters to mainstream market penetration. A Series D of twenty-five million dollars is raised at a two-hundred-million-dollar post-money valuation, representing a two-times step-up that reflects reduced risk but ongoing commercial

scaling needs. This results in twenty percent dilution, leaving the founder with 10 percent ownership.

This progression from eighty percent to twenty percent across five rounds of financing represents a best-case scenario with no down rounds, no bridge financing and no option pool refreshes. In reality, most healthcare companies experience at least one difficult financing where dilution exceeds twenty-five percent, and option pools are typically refreshed to fifteen to twenty percent of the fully diluted cap table at Series A and again at Series C or D to accommodate executive hiring. When these factors are incorporated, founder ownership in the high-teens or low-twenties represents an optimistic outcome for healthcare companies that successfully scale through late-stage venture financing.

## **Regulatory Complexity and Its Syndication Implications**

The regulatory dimension of healthcare creates syndication dynamics that have no parallel in traditional technology ventures. FDA clearance or approval pathways introduce discrete moments of existential risk that fundamentally shape investor behavior and cap table construction. A software company experiencing slow customer adoption can pivot, adjust pricing, target new segments, or fundamentally reimagine its product without requiring government permission. A medical device company facing an FDA rejection letter has far more limited options and may face catastrophic consequences from a single regulatory decision.

This regulatory binary risk drives investors to insist on syndication as a prerequisite for participation. No healthcare investor wants to be the sole institutional backer of a company facing a pivotal FDA submission, regardless of how compelling the technology or clinical data appears. The result is that healthcare companies face implicit pressure to over-syndicate rounds relative to the capital being raised, bringing in more investors at smaller check sizes to distribute regulatory risk across a wider base.

The specialized knowledge required to navigate FDA pathways introduces another syndication pressure. Investors with deep regulatory expertise command premium valuations because they can materially de-risk the development process through guidance. However, these specialized firms often have smaller fund sizes and cannot provide all the capital required for a round, necessitating syndication with larger, more generalist firms who bring capital but less specific expertise. This creates a barbell syndicate structure where the lead investor provides regulatory strategic but a minority of capital, while the majority of capital comes from participants who are less equipped to add operational value but demand board seats or observation rights to protect their investment.

The downstream effects of regulatory-driven syndication emerge most clearly in governance dynamics. A cap table with five or six institutional investors, each of whom participated specifically because of regulatory risk distribution, creates a board or observer base with potentially divergent risk tolerances. Some investors may push aggressive regulatory strategies that accelerate timelines but increase rejection risk while others may advocate for conservative pathways that extend development but improve approval probability. These tensions, which exist to some degree in all venture-backed companies, are amplified in healthcare where regulatory decisions cannot be easily reversed or iterated upon.

The compounding effect of regulatory syndication becomes apparent in subsequent rounds. As the company approaches regulatory submission, new investors demand even broader syndication to distribute the submission risk. Post-clearance or approval, the syndication imperative shifts to commercial risk distribution, but the cap table is already crowded with regulatory-focused investors who may have less commercial scaling expertise. The company faces a choice between further dilution to bring in commercial-stage investors or attempting to execute with a syndicate optimized for a previous stage of company development. Either choice carries significant execution risk.

## **Strategic Misalignment Among Healthcare Syndicates**

Beyond regulatory considerations, healthcare syndicates face strategic misalignment challenges that create friction and can force suboptimal decision-making. The involvement of corporate venture capital arms from pharmaceutical companies, medical device manufacturers, health systems, and payers introduces strategic investors whose objectives extend beyond pure financial returns. These strategic investors participate in rounds to gain insights into emerging technologies, identify potential acquisition targets, or secure preferential partnership terms. While their participation can be valuable for validation and business development, it also introduces complexity around competitive conflicts, information sharing, and exit expectations.

A diagnostic company raising a Series B might include both a strategic investor from a major laboratory services company and a venture firm that has portfolio companies developing competing diagnostics. The lab services corporate venture arm wants to ensure its parent company maintains preferential pricing and distribution rights, while the venture firm wants maximum flexibility to partner with any lab network that offers the best commercial terms. These conflicting objectives can paralyze business development decisions, forcing the company to either navigate a complex political process among its investors or make suboptimal commercial choices to maintain syndicate harmony.

The exit expectation misalignment represents an even more fundamental challenge. Pure financial venture investors typically target a five to seven-year holding period and expect returns through either acquisition or initial public offering. Strategic investors, particularly corporate venture arms, often have more patient capital and may prefer the company remains independent as a long-term partner rather than being acquired by a competitor. This creates tension as the company approaches potential acquisition discussions, with some syndicate members pushing for an aggressive acquisition price negotiation while others quietly hope the deal falls through.

Healthcare-specific investors and generalist technology investors within the same syndicate often harbor different risk tolerances and timeline expectations that can create strategic paralysis. A specialized digital health investor understands that contracting cycles are measured in years and that initial contracts may be pilot

programs with modest revenue. A generalist technology investor accustomed to sales cycles may view these extended timelines as execution failure and push for aggressive pivots that demonstrate faster revenue growth but potentially sacrifice strategic positioning. The company finds itself mediating between incompatible frameworks for evaluating success, which consumes management attention and drive suboptimal strategy.

## **The Reimbursement Timeline Problem**

While regulatory risk is well understood by healthcare investors, reimbursement timeline risk remains surprisingly underappreciated in its impact on dilution and syndication dynamics. Medical technologies that receive FDA clearance face an entirely separate gauntlet of securing payer coverage and adequate reimbursement process that can extend three to seven years beyond regulatory clearance. This reimbursement timeline creates a capital consumption challenge that forces additional financing rounds specifically to fund the working capital and commercial infrastructure required to drive payer adoption.

The economics of payer contracting are particularly punishing for startups. Early health system or payer contracts are typically structured as pilot programs with limited scope, low unit volumes, and reduced pricing that may not cover the full loaded cost of service delivery. The company must fund these money-losing initial contracts to generate the real-world evidence and case studies required to negotiate broader, more economically favorable contracts. This evidence generation and commercial scaling process can easily consume thirty to fifty million dollars before the company reaches breakeven unit economics at scale.

The dilution implications are severe. A healthcare company that successfully navigates FDA clearance and raises a Series C to fund commercial scaling may find itself raising a Series D eighteen months later not because it failed to execute but because payer contracting timelines stretched longer than projected. This additional round, which might not have been necessary for a pure software play that could

revenue more predictably, introduces another twenty to twenty-five percent dilution event that was not in the original financial model.

The syndication dynamics around reimbursement risk differ from regulatory risk. While regulatory risk is binary and acute, reimbursement risk is gradual and cumulative. Investors evaluate reimbursement progress through metrics like pipeline of payer conversations, letters of intent, pilot program conversions, and average contract value rather than single pass-fail moments. This creates a different form of investor anxiety that can manifest as pressure for premature revenue growth at the expense of strategic payer positioning. Some syndicate members may push for aggressive direct-to-consumer sales to demonstrate revenue traction even when the long-term business model requires payer reimbursement for sustainability.

The compounding challenge emerges when reimbursement timelines extend beyond initial projections. Investors who underwrote a Series C based on assumptions of achieving positive unit economics within two years become increasingly nervous that the timeline extends to three years, and this anxiety can manifest in terms for the Series D that are more punitive than earlier rounds. Down rounds, ratchet provisions, or pay-to-play structures become more likely, introducing dilution beyond the baseline level from selling new shares.

## **Defensive Strategies for Cap Table Management**

Given these syndication and dilution challenges, sophisticated healthcare founders employ several defensive strategies to maintain ownership and control through multiple financing rounds. The most fundamental strategy is ruthless capital efficiency in the pre-product-market-fit phase, extending runway through creative approaches to clinical validation and regulatory strategy that minimize the number of institutional financing rounds required.

Many successful healthcare entrepreneurs bootstrap or use non-dilutive capital to reach meaningful clinical or regulatory milestones before raising institutional Series A capital. Non-dilutive funding sources including Small Business Innovation Re

grants, foundation funding, disease-specific nonprofit research grants, and strategic partnerships with reduced upfront payments but favorable economics can collectively fund one to two million dollars of early development work. By reaching FDA clearance or compelling clinical evidence with this non-dilutive capital, founders enter institutional fundraising with dramatically improved bargaining power, enabling them to raise larger rounds at higher valuations with less dilution.

Secondary share sales represent another defensive strategy that remains underutilized in healthcare ventures. As companies reach Series C or D with meaningful de-risk through regulatory clearance and initial commercial traction, founder secondary sales can provide liquidity and reduce the personal financial pressure that sometimes leads to premature exits. However, secondary sales must be structured carefully to avoid signaling lack of confidence to investors, typically limiting founder sales to ten to twenty percent of primary round size and pricing secondary shares at a modest discount to primary shares.

The composition of syndicates matters as much as their size. Founders who proactively construct syndicates with a clear lead investor who can provide both current round capital and meaningful reserves for future rounds reduce the need to continually add new investors in subsequent financings. Healthcare companies that raised a Series A from a specialized healthcare fund with sufficient fund size and strong portfolio construction to lead the Series B and participate meaningfully in the Series C maintain more concentrated cap tables with fewer competing voices. While this concentration creates dependency on a single investor relationship, it also preserves founder ownership by limiting new investor dilution.

Aggressive option pool management can significantly impact founder dilution. Many founders passively accept investor demands for large option pools in early rounds, realizing that unissued options from the pool dilute founders but not investors who hold preferred shares. Negotiating smaller initial option pools and refreshing them only as needed based on actual hiring plans rather than theoretical worst-case scenarios can preserve several percentage points of founder ownership across multiple rounds.

Liquidation preference negotiation represents a final defensive lever. While most healthcare venture rounds involve standard one-times non-participating liquidation preferences, down rounds or difficult financings may introduce participating preferences or higher multiple preferences that dramatically affect founder economic outcomes in moderate exit scenarios. Founders should model various exit scenarios with different preference structures to understand the true economic impact of different term sheet structures. In some cases, accepting additional dilution to maintain standard one-times non-participating preferences is more founder-friendly than accepting less nominal dilution with punitive preference terms.

## **Alternative Financing Structures in Healthcare**

Beyond traditional equity syndication, healthcare entrepreneurs are increasingly exploring alternative financing structures that can reduce dilution while still providing necessary capital for growth. Revenue-based financing has emerged as a viable option for healthcare companies that have achieved regulatory clearance and are generating meaningful revenue, even if not yet profitable. This structure provides growth capital in exchange for a percentage of monthly revenue until a predetermined multiple of the investment is repaid, typically 1.5 to 2.5 times. While more expensive than equity on a pure cost of capital basis, revenue-based financing avoids dilution and can be particularly attractive for companies with predictable recurring revenue streams from payer contracts.

Venture debt has become increasingly accessible for healthcare companies with institutional venture backing and clear pathways to profitability. Debt providers typically extend twelve to thirty-six months of debt financing equal to thirty to fifty percent of the most recent equity round, providing valuable runway extension with minimal dilution. The warrants that accompany venture debt do introduce modest dilution, typically one to two percent of the company, but this represents a fraction of the dilution from a full equity round. Healthcare companies that use venture debt strategically to bridge to the next major milestone can reduce the number of equity rounds required and preserve meaningful founder ownership.

Strategic partnerships with pharmaceutical companies, medical device manufacturer or health systems can provide alternative funding for specific development programs or commercial initiatives. These partnerships typically involve upfront payments, milestone payments, and royalty or revenue sharing arrangements that provide capital without direct equity dilution. However, these partnerships introduce strategic constraints around product development direction, commercialization approach and potential exit paths that must be weighed against the dilution avoidance benefits.

Some healthcare entrepreneurs are exploring novel structures like rights offerings to existing shareholders, which allow founders to participate in funding rounds proportionally to their ownership rather than being diluted by new investors. While uncommon in venture-backed companies, these structures are more prevalent in family offices and high-net-worth investor syndicates where existing shareholders have both capital and conviction to fund ongoing development. The challenge with rights offerings is that they require founders to contribute new capital to maintain their ownership percentage, which assumes founders have liquidity, which is most often not in the early years.

## **When Dilution Becomes Existential**

The ultimate risk of poorly managed syndication and dilution is not simply reduced founder ownership but complete loss of control and motivation. Founders who raise late-stage financing rounds holding single-digit equity stakes face difficult psychological challenges that can impact company performance. When a founder owns five percent of a company valued at one hundred million dollars, their effective ownership is worth five million dollars pre-tax, which sounds meaningful in absolute terms but represents a relatively modest outcome after ten years of entrepreneurial effort and personal risk. The same founder might rationally decide that pushing for a two-hundred-million-dollar exit that yields them ten million dollars is not sufficiently differentiated from accepting a one-hundred-fifty-million-dollar acquisition offer that yields them seven-point-five million dollars to justify the additional years of effort and risk.

This misalignment between founder motivation and investor return optimization becomes particularly acute in healthcare where exit values often fall in the one-hundred to three-hundred-million-dollar range for successful companies. A founder with fifteen percent ownership of a company acquired for two hundred million dollars realizes thirty million dollars before taxes, which represents life-changing wealth. A founder with strong alignment with investors to optimize exit value. The same founder with seven percent ownership realizes fourteen million dollars, which is meaningful but may not justify rejecting a one-hundred-fifty-million-dollar offer that would net them ten point-five million dollars.

The control implications of extreme dilution extend beyond economics to operational decision-making. Founders holding less than ten percent ownership in companies with multiple syndicate members may find themselves without a board seat or with reduced influence over strategic direction. While strong board relationships and founder respect can preserve influence beyond formal ownership, the reality is that as founder ownership declines, their leverage in governance disputes decreases proportionally.

Some healthcare companies respond to extreme founder dilution by implementing recapitalization plans that reset founder ownership in exchange for modified vesting schedules or reduced compensation. These recapitalizations acknowledge that founder motivation is critical to company success and that restoring founder ownership to meaningful levels, even if it moderately dilutes existing investors, is worthwhile if it meaningfully increases company value through improved execution. However, these recapitalizations are complex to negotiate and can create resentment among investors who feel they are subsidizing founder mistakes in earlier capital raising decisions.

## **Conclusion: Rethinking Capital Efficiency**

The syndication and dilution dynamics facing healthcare entrepreneurs demand fundamental rethinking of capital efficiency and financing strategy from the earliest stages of company formation. The traditional venture capital model, designed

primarily for software companies with rapid scaling potential and manageable capital requirements, translates poorly to healthcare ventures with extended regulatory timelines, capital-intensive clinical validation requirements, and complex reimbursement pathways. Healthcare founders who approach financing with the assumptions that guide enterprise SaaS entrepreneurs will likely find themselves with inadequate ownership stakes long before their companies reach meaningful liquidity events.

The path forward requires healthcare entrepreneurs to become sophisticated capital strategists who understand that preserving founder ownership requires active management across multiple dimensions. This includes maximizing non-dilutive funding sources in early development stages, constructing syndicates with an eye toward long-term cap table health rather than optimizing for current round dynamics, negotiating aggressively on option pool sizing and liquidation preferences, and exploring alternative financing structures that reduce equity dilution for late-stage growth capital.

More fundamentally, healthcare entrepreneurs should recognize that the total amount of capital raised is not a vanity metric to be maximized but rather a liability to be carefully managed. Each dollar of institutional capital comes with dilution, governance complexity, and strategic constraints that compound over multiple financing rounds. The most successful healthcare founders are those who find creative approaches to reaching critical milestones with less capital, not those who raise the largest rounds at the highest valuations without considering the cumulative dilution impact.

The syndication imperative in healthcare is real and driven by legitimate needs for specialized expertise and risk distribution, but it need not result in founders becoming minority stakeholders in their own companies. By understanding the unique dynamics of healthcare financing, constructing syndicates strategically, employing defensive cap table management techniques, and exploring alternative financing structures, healthcare entrepreneurs can navigate the complex journey from formation to exit while maintaining sufficient ownership to make the extraordinary effort worthwhile. The goal is not to eliminate dilution, which is impossible in

venture-backed companies, but to manage it thoughtfully such that founders, employees, and investors all maintain sufficient alignment to drive toward optimal outcomes. In an industry where the ultimate measure of success is not just financial returns but impact on human health, preserving founder motivation and control through reasonable ownership stakes is not just good business practice but an ethical imperative.

[← Previous](#)

[Next](#)

## Discussion about this post

[Comments](#)

[Restacks](#)



Write a comment...